AlphaRx has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other markets.
In humans, these interferon levels double as early as four hours after administration of the drug. After 12-24 hours the levels can be one hundred or even several thousand fold higher, with maximum level achieved at 48 hours.
As per the agreement, Venturepharm is expected to be the primary supplier of AlphaRx’s worldwide requirements for the compound.
Ruby Hui, president of China operations at AlphaRx, said: “This contract manufacturing relationship marks another important step in our strategic plan for the development of ARX1088. We are currently focused on commercializing ARX1088 in China and South America.
“The supply agreement provides us with an uninterrupted supply of product to complete our planned clinical trials in China. It also assures that there will not be a gap between the supply of clinical materials and the supply of product for commercialisation, the agreement potentially eliminates manufacturing delays that could affect bringing ARX1088 to market.”